{"id":"W2947681783","doi":"10.1002/ejhf.1532","title":"Sacubitril/Valsartan Eligibility and Outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: Bridging Between European Medicines Agency/Food and Drug Administration Label, the PARADIGM-HF Trial, ESC Guidelines, and Real World","year":2019,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Care Foundation","funders":"Servier; Boston Scientific Corporation; Daiichi Sankyo Europe; ResMed; Edwards Lifesciences; European Society of Cardiology; Sanofi; AstraZeneca; Bayer; Boehringer Ingelheim","keywords":"Medicine; Sacubitril; Heart failure; Sacubitril, Valsartan; Valsartan; Ejection fraction; Enalapril; Guideline; Internal medicine; Cardiology; Intensive care medicine; Blood pressure; Angiotensin-converting enzyme","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004539291,0.0002015069,0.0006361651,0.0005154025,0.0002165645,0.0008862063,0.0005439399,0.0005139562,0.001360276],"category_scores_gemma":[0.006774995,0.0001375531,0.0006298834,0.001141163,0.000182227,0.0006850199,0.0007390195,0.0006120178,0.0002705656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003372167,"about_ca_system_score_gemma":0.0005626292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001519995,"about_ca_topic_score_gemma":0.004080812,"domain_scores_codex":[0.9969838,0.001213926,0.0004986709,0.0005174123,0.0005713308,0.0002148645],"domain_scores_gemma":[0.9910263,0.001693175,0.0054321,0.0006304301,0.0006743947,0.0005435849],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004656223,0.0001869618,0.9837767,0.0001198407,0.0004624799,0.00009067643,0.00003448457,0.0001713474,0.000217161,0.0001413839,0.002872453,0.007270223],"study_design_scores_gemma":[0.0007823441,0.0005597671,0.995565,0.00006267408,0.0003361586,0.0002594587,0.00006695939,0.0006695565,0.0001665751,0.0001117081,0.001406075,0.00001363758],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988893,0.0011296,0.0003909926,0.000329334,0.00003009241,0.0001239374,0.007172118,0.00001572698,0.001915138],"genre_scores_gemma":[0.9878631,0.0002172868,0.0003857605,0.0002562241,0.00008268077,0.0001474758,0.01078308,0.000009150568,0.0002552994],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004539291,"threshold_uncertainty_score":0.02400637,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04177887841795871,"score_gpt":0.3317047626631524,"score_spread":0.2899258842451937,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}